With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline. This potential new treatment option for breast cancer could eliminate estrogen receptors from cells and potentially redefine the standard of care for hormone receptor positive cancer, one of the most common types of cancer in women.
